Tivozanib Plus Nivolumab vs Tivozanib Monotherapy in RCC Following an Immune Checkpoint Inhibitor The Phase 3 TiNivo-2 Study : Episode 1

First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape

March 31, 2025

By Sumanta Pal, MD, FASCO
Benjamin Gerendash, MSN, RN, AGACNP-BC

Opinion

Video

Experts discuss first-line treatment strategies for renal cell carcinoma (RCC) in 2025, navigating the evolving therapeutic landscape.

EP: 1.First-Line RCC Treatment in 2025: Navigating the Evolving Therapeutic Landscape

EP: 2.Sequencing Strategies in RCC: Optimizing Treatment Selection After IO-Based Therapy

EP: 3.VEGFR-TKI Tivozanib: Rational Treatment Selection Post-ICI Progression

EP: 4.Tivozanib Monotherapy Efficacy Profile and Clinical Management Strategies in Advanced RCC

EP: 5.Optimizing VEGFR-TKI Therapy: Perspectives on Patient Selection and Management Strategies in Clinic

EP: 6.TiNivo-2 Phase 3 Trial: Survival Data and Practical Approaches to Dose Management in Practice

EP: 7.Quality of Life and Treatment Experience: Patient-Reported Outcomes from TiNivo-2

EP: 8.Optimizing RCC Treatment: Integrating Patient-Reported Outcomes and Clinician Insights

Newsletter

Stay up to date on recent advances in oncology nursing and patient care.

Recent Videos

3 KOLs are featured in this series.

3 KOLs are featured in this series.

Image of a woman with blond hair wearing a headset and a hospital badge over a blouse in front of a watercolor Oncology Nursing News background

Latest Conference Coverage

The Reality of VTE: How to Best Address in Cancer Care

AI Decision Support Tools Serve as Copilots in Cancer Care

Toxicity Monitoring, Management Crucial for Tarlatamab in ES-SCLC

Cancer Drug Repository Network Yields $18M in Patient Savings

View More Latest Conference Coverage

Editorial Board

CancerNetwork.com

TargetedOnc.com

Terms & Conditions

Do Not Sell My Information

Contact Info

259 Prospect Plains Rd, Bldg H,
Cranbury, NJ 08512

© 2025 MJH Life Sciences

All rights reserved.